U.S. markets closed
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • Dow 30

    34,347.03
    +152.97 (+0.45%)
     
  • Nasdaq

    11,226.36
    -58.96 (-0.52%)
     
  • Russell 2000

    1,869.19
    +5.67 (+0.30%)
     
  • Crude Oil

    76.28
    -1.66 (-2.13%)
     
  • Gold

    1,754.00
    +8.40 (+0.48%)
     
  • Silver

    21.43
    +0.06 (+0.29%)
     
  • EUR/USD

    1.0405
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    3.6910
    -0.0150 (-0.40%)
     
  • GBP/USD

    1.2091
    -0.0023 (-0.19%)
     
  • USD/JPY

    139.1000
    +0.5100 (+0.37%)
     
  • BTC-USD

    16,515.48
    +23.05 (+0.14%)
     
  • CMC Crypto 200

    386.97
    +4.32 (+1.13%)
     
  • FTSE 100

    7,486.67
    +20.07 (+0.27%)
     
  • Nikkei 225

    28,283.03
    -100.06 (-0.35%)
     

MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers

MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers (VLUs).

  • The study randomized 120 patients, of which 119 patients were treated by either EscharEx (n=46), a gel vehicle (n=43), or a non-surgical standard-of-care consisting of either enzymatic or autolytic debridement (n=30).

  • Also See: MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients.

  • The study met its primary endpoint, demonstrating that patients treated with EscharEx showed a higher incidence of complete debridement during the 14-day measurement period within up to 8 applications than patients treated with gel vehicle (EscharEx: 63% vs. gel vehicle: 30%).

  • The incidence of complete debridement of the non-surgical standard-of-care arm during the same 14-day measurement period was 13%.

  • In addition, no safety concerns were identified. EscharEx was well-tolerated, and overall safety was comparable between the arms.

  • Patient follow-up is ongoing and additional data is expected in the second quarter of 2022.

  • MediWound expects to request an end-of-Phase 2 meeting with the FDA in 2H of 2022.

  • Designed for the outpatient setting, EscharEx is an easy-to-use concentrate of proteolytic enzymes enriched in bromelain for daily topical applications.

  • Price Action: MDWD shares closed at $2.43 on Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.